



January 20, 2015

## Researchers to Present New Data on Asfotase Alfa in Children with Hypophosphatasia (HPP) as well as Burden of Disease Data in Adults with HPP at ENDO 2015 Annual Meeting

CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers will present new functional and quality-of-life data from clinical studies in children with hypophosphatasia (HPP) who were treated with asfotase alfa for at least three years at the Endocrine Society's 97<sup>th</sup> Annual Meeting and Expo (ENDO). Researchers will also present data from two patient-reported surveys characterizing the burden of HPP in adults. Abstracts summarizing these studies were published on the ENDO website and can be accessed using the links below. The ENDO annual meeting will be held March 5-8, 2015, in San Diego.

The following abstracts will be presented in a poster session on Friday, March 6, 2015, from 1:00 to 3:00 p.m., Pacific Standard Time (PST):

- Abstract FRI-224: "Improved Activities of Daily Living and Physical Function, with Decreased Pain, in Children with Hypophosphatasia Treated for Three Years with Asfotase Alfa: Results from the Childhood Health Assessment Questionnaire and the Pediatric Outcomes Data Collection Instrument," Phillips, et al.

Accessible at: <https://endo.confex.com/endo/2015endo/webprogram/Paper21021.html>

- Abstract FRI-240: "Burden of Disease in Adult Patients with Hypophosphatasia: Results from Patient-Reported Outcome Surveys," Weber, et al.

Accessible at: <https://endo.confex.com/endo/2015endo/webprogram/Paper20871.html>

The following abstract will be presented in an oral session on Saturday, March 7, 2015, from 11:30 a.m. to 1:00 p.m., Pacific Standard Time (PST):

- Abstract OR29-4: "Significantly Improved Muscle Strength, Running Speed, and Agility in Children with Hypophosphatasia Treated with Asfotase Alfa," Phillips, et al.

Accessible at: <https://endo.confex.com/endo/2015endo/webprogram/Paper20906.html>

### About Hypophosphatasia (HPP)

HPP is a genetic, chronic and progressive ultra-rare metabolic disease characterized by defective bone mineralization that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.<sup>1-5</sup>

HPP is caused by mutations in the gene encoding an enzyme known as tissue non-specific alkaline phosphatase (TNSALP).<sup>1,2</sup> The genetic deficiency in HPP can affect people of all ages.<sup>1</sup> HPP is classified by the age of the patient at the onset of symptoms of the disease, and infantile- and juvenile-onset HPP is defined as manifestation of the first symptom prior to 18 years of age.

HPP can have devastating consequences for patients at any stage of life.<sup>1</sup> In a natural history study, infants who had their first symptom of HPP within the first 6 months of life had high mortality, with an overall mortality rate of 73% at 5 years.<sup>6</sup> In these patients, mortality is primarily due to respiratory failure.<sup>1,5,7</sup> In patients surviving to adolescence and adulthood, long-term clinical sequelae include recurrent and non-healing fractures, debilitating weakness, severe pain and the requirement for ambulatory assistive devices such as wheelchairs, wheeled walkers and canes.<sup>1,4</sup>

### About Asfotase Alfa

Asfotase alfa is an investigational, highly innovative, first-in-class enzyme replacement therapy. Asfotase alfa is designed to address the underlying cause of HPP by aiming to restore the genetically defective metabolic process, thereby preventing or reversing the severe and potentially life-threatening complications of life-long dysregulated mineral metabolism.

In 2013, the FDA granted Breakthrough Therapy designation for asfotase alfa. A Breakthrough Therapy designation is designed to expedite the development of a drug to treat a serious or life-threatening disease when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. In 2014, Alexion completed regulatory filings in the U.S., Europe and Japan for asfotase alfa for the treatment of HPP.

## About Alexion

Alexion is a biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets Soliris<sup>®</sup> (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in nearly 50 countries for the treatment of PNH and in nearly 40 countries for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris in additional severe and ultra-rare disorders beyond PNH and aHUS, and is developing other highly innovative biotechnology product candidates, including asfotase alfa, across multiple therapeutic areas. This press release and further information about Alexion can be found at: [www.alexionpharma.com](http://www.alexionpharma.com).

[ALXN-G]

## Safe Harbor Statement

*This news release contains forward-looking statements, including statements related to potential medical benefits of asfotase alfa for hypophosphatasia (HPP). Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including, for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of asfotase alfa for HPP, delays in arranging satisfactory manufacturing capabilities and establishing commercial infrastructure for asfotase alfa for HPP, the possibility that results of clinical trials are not predictive of safety and efficacy results of asfotase alfa in broader or different patient populations, the risk that third party payors (including governmental agencies) will not reimburse for the use of asfotase alfa (if approved) at acceptable rates or at all, the risk that estimates regarding the number of patients with asfotase alfa and observations regarding the natural history of patients with asfotase alfa are inaccurate, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2014. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.*

## References

1. Rockman-Greenberg C. Hypophosphatasia. *Pediatr Endocrinol Rev.* 2013; 10(suppl 2):380-388.
2. Whyte MP. Hypophosphatasia: nature's window on alkaline phosphatase function in humans. In: Bilezikian JP, Raisz LG, Martin TJ, eds. *Principles of Bone Biology*. Vol 1. 3rd ed. San Diego, CA: Academic Press; 2008:1573-1598.
3. Whyte MP, Greenberg CR, Salman N, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. *N Engl J Med.* 2012; 366(10):904-913.
4. Seshia SS, Derbyshire G, Haworth JC, Hoogstraten J. Myopathy with hypophosphatasia. *Arch Dis Child.* 1990; 65(1):130-131.
5. Baumgartner-Sigl S, Haberlandt E, Mumm S, et al. Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T > C, p.M226T; c.1112C > T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. *Bone.* 2007; 40(6):1655-1661.
6. Whyte MP, Leung E, Wilcox W, et al. Hypophosphatasia: a retrospective natural history study of the severe perinatal and infantile forms. Poster presented at the 2014 Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting, Vancouver, B.C., Canada, May 5, 2014. Abstract 752416.
7. Whyte MP, Rockman-Greenberg C, Hofmann C, et al. Improved survival with asfotase alfa treatment in pediatric patients with hypophosphatasia at high risk of death. Poster presented at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, Houston, September 14, 2014. Abstract 1097.

Alexion:

Media

Irving Adler, 203-271-8210

Executive Director, Corporate Communications

or

Kim Diamond, 203-439-9600

Senior Director, Corporate Communications

or

Investors

Elena Ridloff, CFA, 203-699-7722  
Executive Director, Investor Relations

Source: Alexion Pharmaceuticals, Inc.

News Provided by Acquire Media